71 completed, 68 recruiting, 44 unknown, 19 terminated. 114 Phase 2, 74 Phase 1, 28 Phase 3, 16 Not applicable, 4 Phase 4.
Follow Advanced Breast Cancer: new trials by email Literature Review of Advanced Breast Cancer trials Research Report on Advanced Breast Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Learn About the Study Medicine Called PF-08165784 in People With PIK3CA-Mutated Advanced or Metastatic Solid Tumors PF-08165784, Fulvestrant, Atirmociclib - Advanced Breast Cancer, Advanced or Metastatic Breast Cancer | Phase 1 | Not yet recruiting | Pfizer | 268 | 2026-11-09 | 2026-10-27 |
| Trastuzumab Deruxtecan and Lovastatin in HER2-low and Ultralow Advanced or Metastatic Breast Cancer Trastuzumab deruxtecan, Lovastatin - Breast Cancer, Advanced Breast Cancer | Phase 2 | Not yet recruiting | Washington University School of Medicine | 60 | 2026-10-31 | 2026-09-22 |
| A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer ZOLADEX - Advanced Breast Cancer, Early Breast Cancer | Phase 1 | Recruiting | TerSera Therapeutics LLC | 176 | 2026-10-30 | 2026-10-13 |
| A Phase II Study of Zongertinib Plus Fulvestrant in Participants With HR-positive/HER2-negative Advanced Breast Cancer Harboring HER2 Mutations. Zongertinib (BI 1810631), Fulvestrant - Advanced Breast Cancer, Hormone Receptor Positive / HER2-negative Breast Cancer | Phase 2 | Not yet recruiting | MedSIR | 25 | 2026-10-04 | 2026-06-01 |
| Exploring Curative Model for Advanced Breast Cancer: a Single-center, Prospective Phase II Clinical Study Advanced Breast Cancer | Not yet recruiting | Henan Cancer Hospital | 147 | 2026-10-01 | 2026-10-22 | |
| Albumin-Bound Paclitaxel (Ⅱ) in Patients With Advanced Breast Cancer Experimental Group, control group - Breast Cancer, HER2-negative Breast Cancer | Not yet recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 1372 | 2026-10-01 | 2026-10-27 | |
| Trastuzumab Rezetecan Followed by Pyrotinib, and Trastuzumab Combined With Capecitabine as First-line Treatment for Advanced HER2-positive Breast Cancer Trastuzumab Rezetecan, Pyrotinib, trastuzumab - HER2 + Breast Cancer, Advanced Breast Cancer | Phase 2 | Not yet recruiting | Fujian Cancer Hospital | 50 | 2026-09-30 | 2026-08-14 |
| SHIELD: Surveillance of HR+/HER2- : Implementing ESR1m Long-term Monitoring and Detection in 1L aBC Blood sampling - Advanced Breast Cancer | Not yet recruiting | AstraZeneca | 3000 | 2026-09-30 | 2026-07-14 | |
| T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXd Trastuzumab deruxtecan, Trastuzumab, Pertuzumab - Advanced Breast Cancer, Metastatic Breast Cancer | Phase 3 | Recruiting | Daiichi Sankyo | 200 | 2026-09-18 | 2026-10-16 |
| A Study of [68Ga]Ga-DWJ155 in Adult Patients With Solid Tumors [68Ga]Ga-DWJ155 - Advanced Gastroesophageal Adenocarcinoma, Advanced Breast Cancer | Phase 1 | Recruiting | Novartis Pharmaceuticals | 66 | 2026-09-08 | 2026-10-13 |
| Metronomic Oral Paclitaxel Monotherapy for Advanced HER2-Negative Breast Cancer: A Two-Stage Dose-Finding and Expansion Study Paclitaxel Oral Solution (50mg/qd), Paclitaxel Oral Solution (100mg/TIW), Paclitaxel Oral Solution (OTD) - Advanced Breast Cancer, HER2-negative Breast Cancer | Phase 2 | Recruiting | Zhejiang Cancer Hospital | 73 | 2026-08-04 | 2026-08-11 |
| Efficacy and Safety of Utidelone Capsule and Utidelone Injection in Patients With HER-2 Negative Advanced Breast Cancer Utidelone Capsule, Utidelone Injection, Capecitabine - Advanced Breast Cancer | Phase 3 | Not yet recruiting | Beijing Biostar Pharmaceuticals Co., Ltd. | 308 | 2026-08-01 | 2026-07-06 |
| A Phase II Study of AK146D1 Combined With AK112 in Advanced Breast Cancer AK146D1 for injection, AK112 Injection - Advanced Breast Cancer | Phase 2 | Recruiting | Akeso | 200 | 2026-07-17 | 2026-07-22 |
| Timing of ctDNA Testing in Advanced Breast Cancer Advanced Breast Cancer | Recruiting | Geneplus-Beijing Co. Ltd. | 400 | 2026-07-08 | 2026-09-15 | |
| Real-world Study of Pyrotinib-containing Regimens of Advanced HER2-positive Breast Cancer Pyrotinib, Trastuzumab Rezetecan - HER2 + Breast Cancer, Advanced Breast Cancer | Phase 4 | Recruiting | Peking University People's Hospital | 500 | 2026-07-06 | 2026-07-13 |
| Decision Support Tool for Patients With Advanced Breast Cancer Decision Support Tool - Breast Cancer Metastatic, Advanced Breast Cancer | Not applicable | Recruiting | Weill Medical College of Cornell University | 100 | 2026-06-17 | 2026-08-19 |
| Exploratory Study of SHR-A1811 Via Different Administration Routes in Patients SHR-A1811 - HER2positive, Advanced Breast Cancer | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 60 | 2026-06-10 | 2026-06-11 |
| Efficacy and Safety of Trastuzumab Rezetecan or Trastuzumab Deruxtecan in Advanced Breast Cancer Trastuzumab Rezetecan for Injection (SHR-A1811), Trastuzumab Deruxtecan for Injection (T-DXd) - Advanced Breast Cancer | Phase 2 | Not yet recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 100 | 2026-06-01 | 2026-06-05 |
| Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors RGT-490 - Breast Cancer, Ovarian Cancer | Phase 1 | Recruiting | Regor Pharmaceuticals Inc. | 63 | 2026-06-01 | 2026-07-22 |
| A Clinical Study of SYS6023 Combination Therapy for Advanced Breast Cancer SYS6023, KN026 - Advanced Breast Cancer | Phase 2 | Recruiting | CSPC Megalith Biopharmaceutical Co.,Ltd. | 36 | 2026-05-25 | 2026-06-16 |
Showing 20 of 247. Sign in to see all of them.
Breast Neoplasms (96) · Neoplasm Metastasis (11) · Neoplasms (10) · Triple Negative Breast Neoplasms (10) · Carcinoma, Non-Small-Cell Lung (6) · Endometrial Neoplasms (6) · Lung Neoplasms (6) · Ovarian Neoplasms (6) · Colorectal Neoplasms (4) · Stomach Neoplasms (4) · Brain Neoplasms (3) · Colonic Neoplasms (3) · Fallopian Tube Neoplasms (3) · Prostatic Neoplasms (3) · Breast Diseases (2)
Neoplasms by Site (100) · Neoplasms (97) · Skin Diseases (97) · Skin and Connective Tissue Diseases (97) · Breast Diseases (95) · Pathological Conditions, Signs and Symptoms (13) · Neoplasms by Histologic Type (12) · Urogenital Diseases (12) · Neoplastic Processes (11) · Pathologic Processes (11) · Urogenital Neoplasms (11) · Digestive System Diseases (10) · Digestive System Neoplasms (10) · Endocrine Gland Neoplasms (10) · Endocrine System Diseases (10)
Fulvestrant (48) · Letrozole (20) · Trastuzumab (15) · palbociclib (15) · Anastrozole (13) · Capecitabine (13) · ribociclib (9) · Goserelin (8) · Paclitaxel (8) · trastuzumab deruxtecan (8) · Docetaxel (7) · Everolimus (7) · abemaciclib (7) · exemestane (7) · Alpelisib (6)
MedSIR (13) · AstraZeneca (11) · Pfizer (8) · Fudan University (7) · Novartis Pharmaceuticals (7) · Spanish Breast Cancer Research Group (5) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (5) · CSPC Ouyi Pharmaceutical Co., Ltd. (4) · Henan Cancer Hospital (4) · Jiangsu HengRui Medicine Co., Ltd. (4) · The First Affiliated Hospital with Nanjing Medical University (4) · Wenjin Yin (4) · Ahon Pharmaceutical Co., Ltd. (3) · Bristol-Myers Squibb (3) · Duke University (3)
China (93) · United States (76) · Spain (36) · Italy (27) · France (26) · South Korea (20) · United Kingdom (20) · Germany (17) · Canada (16) · Australia (15) · Belgium (15) · Japan (12) · Czechia (11) · Poland (11) · Austria (10)
Wenjin Yin, M.D. (5) · Binghe Xu (3) · Denys Shay, MD (3) · Shirley Wang, PhD, ScM (3) · Jackie Walling, MBChB, PhD (2) · Min Yan, Chief physician (2) · Adam Ostrowski, MD (1) · Agnes Jager, MD, PhD (1)
PMID 20632084, PMID 20938664, PMID 21931708, PMID 22547604, PMID 23569309, PMID 23632474, PMID 23801303, PMID 23953056, PMID 24104881, PMID 24674873, PMID 25880008, PMID 26578730, PMID 27121067, PMID 27902470, PMID 28228842, PMID 28245951, PMID 28314691, PMID 28445973, PMID 28650446, PMID 29860922, PMID 29948356, PMID 30042390, PMID 30641299, PMID 30792217, PMID 30796032, PMID 31194225, PMID 31194228, PMID 31305131, PMID 31583931, PMID 31826360, PMID 32043762, PMID 32193378, PMID 32271794, PMID 32390277, PMID 32544366, PMID 32562118, PMID 32700765, PMID 32787449, PMID 32816222, PMID 32919527, PMID 33084020, PMID 33534046, PMID 33591468, PMID 33643905, PMID 33743103, PMID 33763756, PMID 33769862, PMID 33835229, PMID 33893289, PMID 34037241
2023 (4), 2017 (3), 2019 (3), 2016 (2), 2018 (2), 2025 (2), 2005 (1), 2015 (1), R01CA281861 (1), R01CA291768 (1)